Company Profile For Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system. Using its ProCellEx system, the Company is developing a pipeline of recombinant therapeutic proteins based on its plant cell-based expression technology that target pharmaceutical markets and that rely upon known biological mechanisms of action. Its product development candidate, prGCD, is a plant cell expressed recombinant Glucocerebrosidase enzyme (GCD) for the treatment of Gaucher disease. Its product pipeline includes, among other candidates, therapeutic protein candidates for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans, an acetylcholinesterase enzyme-based therapy for biodefense and intoxication treatments and an additional undisclosed therapeutic protein.

BRIEF: For the nine months ended 30 September 2009, Protalix BioTherapeutics Inc. reported no revenues. Net loss increased 4% to $16.5M. Revenues reflect that the Company is still in the development stage. Net loss reflects increased research & development expenses due to higher costs related to consulting & subcontractors associate with research & development expenses. The Company is engaged in development & commercialization of recombinant.